An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
Status:
Completed
Trial end date:
2016-01-31
Target enrollment:
Participant gender:
Summary
This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in
participants with Glaucoma or Ocular Hypertension who completed study FSV5-002. All
participants received Bimatoprost Ocular Insert and wore it for approximately 7 months, then
had the Insert removed and a new insert placed for another 6 months.